Brief: IO Biotech Announces Preliminary Data From Phase 2 Trial Evaluating Io102-Io103 In Combination With Pembrolizumab
23/10/2023 06:08
Oct 23 (Reuters) - IO Biotech Inc IOBT.O :
* ENCOURAGING PRELIMINARY DATA FROM A PHASE 2 TRIAL
EVALUATING
IO102-IO103 IN COMBINATION WITH PEMBROLIZUMAB FOR FIRST-LINE
TREATMENT OF PATIENTS WITH NON-SMALL CELL LUNG CANCER AND
SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK PRESENTED AT THE
EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY (ESMO) CONGRESS
Source text for Eikon: ID:nGNXb6vfTk
Further company coverage: IOBT.O
((Reuters.Briefs@thomsonreuters.com;))